Explore

Rockefeller University Researchers Map Tuberculosis Genetic Networks Using CRISPR Interference to Develop Better Treatments

Rockefeller University Researchers Map Tuberculosis Genetic Networks Using CRISPR Interference to Develop Better Treatments

Researchers at The Rockefeller University have developed a new approach to systematically map the genetic relationships within Mycobacterium tuberculosis (Mtb), the bacterium responsible for tuberculosis (TB). Utilizing CRISPR interference, a technology that allows for the selective reduction of gene activity, the team investigated how disrupting pairs of genes affects bacterial growth. By focusing on genes essential for Mtb's survival, they uncovered thousands of previously unknown genetic interactions, creating the first comprehensive map of its kind for a bacterial pathogen. This map provides new insights into the fundamental biology of TB, including the identification of previously mysterious genes involved in bacterial energy production. The research also offers a new strategy for developing better treatments by identifying gene pairs whose simultaneous disruption is particularly harmful to the bacterium, leading to the prediction and experimental validation of several promising antibiotic combination...

CSIR-CCMB Researchers Identify Potential Tuberculosis Drug Targets Using CRISPR Technology

CSIR-CCMB Researchers Identify Potential Tuberculosis Drug Targets Using CRISPR Technology

Researchers at the CSIR-Centre for Cellular and Molecular Biology (CCMB) in Hyderabad have identified critical weaknesses in Mycobacterium tuberculosis, the bacterium responsible for tuberculosis (TB). Led by CCMB Director Vinay Kumar Nandicoori, the team mapped the bacterium's protein export machinery, identifying 92 key components and nearly 200 molecular reactions. Through CRISPR-based gene silencing, they reduced the activity of the SecA1 and Tat pathways, leading to a sharp decline in bacterial growth in laboratory cultures and immune cells. This disruption affected the export of over 100 proteins linked to SecA1 and approximately 140 linked to Tat, also damaging the bacterial cell membrane, making it unstable and more permeable. These findings, published in the peer-reviewed journal Molecular & Cellular Proteomics, suggest new potential drug targets for TB, a disease that accounts for nearly a quarter of global cases and about a third of drug-resistant infections.

CEAL4Genomics Program Strengthens Community-Engaged Genomics Research for Health Outcomes

CEAL4Genomics Program Strengthens Community-Engaged Genomics Research for Health Outcomes

The CEAL4Genomics program is actively fostering community engagement in genomics and genetics research to improve health outcomes for all. This initiative recognizes that a person's health is shaped by both their environment and ancestry, and aims to ensure that everyone benefits from scientific advances in genomics. The program supports community-engaged genomics research through sustained relationships between community and academic partners, increased trust and trustworthiness around genomics research, and meaningful collaboration to accelerate genetics and genomics research for health and chronic conditions. Research projects funded by CEAL4Genomics focus on community-engaged study designs, broad community participation, returning findings to participating communities, and impactful genomics research to address health outcome differences.

New Retinal Imaging Method Detects TDP-43 Pathology in Neurodegenerative Diseases

New Retinal Imaging Method Detects TDP-43 Pathology in Neurodegenerative Diseases

Researchers have developed a novel method utilizing a fluorescent ocular tracer, AMDX-8050, to detect TDP-43 pathology in the retina, a key biomarker for several neurodegenerative diseases. This new technique, detailed in a study, aims to provide a simple and non-invasive way to identify conditions such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and limbic-predominant age-related TDP-43 encephalopathy (LATE). The study involved examining cadaveric retinal tissues from individuals with ALS, FTD-TDP-43, and LATE. AMDX-8050 successfully labeled cytoplasmic retinal deposits that co-localized with TDP-43 pathology, showing a dense and varied distribution similar to those found in matched spinal cord and motor cortex tissues. This development suggests a potential new class of retinal tracers with broad applicability for TDP-43 proteinopathies, offering a promising avenue for earlier diagnosis and monitoring of these complex diseases. The research was supported by organizations includi...

Los Angeles Public Health Responses Show Evolving Equity Focus in Disease Outbreaks

Los Angeles Public Health Responses Show Evolving Equity Focus in Disease Outbreaks

Los Angeles has demonstrated an evolving approach to health equity in its public health responses to disease outbreaks over time, according to a recent analysis. Historically, responses to diseases like tuberculosis in the late 19th and early 20th centuries were marked by significant racial and economic discrimination, with public health officials often blaming immigrants and poorer communities and restricting their access to care. Decades later, the HIV/AIDS epidemic saw Los Angeles emerge as a national leader in equitable responses at the city level, passing landmark anti-discrimination laws, though county-level responses were slower. Most recently, the COVID-19 pandemic saw health equity explicitly integrated into public health strategies in Los Angeles and California, with policies aimed at directing resources to communities with the greatest need. Despite these advancements, underlying structural factors continue to create uneven impacts, indicating that while equity is emphasized, sustained effort is...

FDA Clears Metagenomi's IND for MGX-001, a One-Time Genome Editing Therapy for Hemophilia A

FDA Clears Metagenomi's IND for MGX-001, a One-Time Genome Editing Therapy for Hemophilia A

The FDA has cleared Metagenomi Therapeutics' Investigational New Drug (IND) application for MGX-001, its lead genome editing program for hemophilia A. This clearance allows the company to initiate a first-in-human Phase 1/2 trial for the one-time therapy in adults and children with moderately severe to severe hemophilia A. MGX-001 is designed to site-specifically integrate the Factor VIII (FVIII) gene into a 'safe harbor' location within the albumin gene, utilizing the body's native albumin promoter to drive durable, endogenous FVIII production. The therapy uses an adeno-associated virus (AAV) vector for the FVIII gene cassette and a lipid nanoparticle (LNP) to deliver mRNA encoding a proprietary Type V CRISPR nuclease.

U.S. Department of Health and Human Services Seeks Physicians for Public Health Roles in Atlanta

U.S. Department of Health and Human Services Seeks Physicians for Public Health Roles in Atlanta

The U.S. Department of Health and Human Services (HHS) is actively recruiting physicians for public health positions within the National Center for Emerging and Zoonotic Infectious Diseases, located in Atlanta, Georgia. The job announcement specifies stringent qualification requirements, including a Doctor of Medicine or equivalent degree from an accredited U.S. or Canadian school, or a foreign medical school degree with demonstrated equivalency. Candidates must also possess a current, active, full, and unrestricted physician's license from a U.S. state or territory, and at least one year of supervised clinical experience. The roles involve leading clinical and scientific research programs, providing epidemiological expertise for disease surveillance and outbreak investigations, and serving as subject matter experts for public health initiatives. The announcement will close once 50 applications are received or by the specified closing date, whichever comes first.

Kenya Begins 42-Day Countdown to Ebola-Free Status After Successful Public Health Response

Kenya Begins 42-Day Countdown to Ebola-Free Status After Successful Public Health Response

Kenya has initiated a 42-day countdown towards being declared Ebola-free, following the discharge of its last Ebola patient. This significant step comes after nine individuals were infected when a man traveled from the Democratic Republic of Congo (DRC) to Kenya in early October. The outbreak resulted in two deaths, including the index patient and a 65-year-old relative. Seven patients have successfully recovered, and all contacts have completed their follow-up monitoring. Kenya's Cabinet Secretary of Health, Aden Duale, MBA, confirmed these developments in a media briefing. The Africa Centres for Disease Control and Prevention Director-General, Jean Kaseya, MD, MPH, praised Kenya's robust public health response, highlighting its effectiveness in early detection, contact tracing, clinical care, and community engagement. Kenya is the third African nation outside the DRC to experience a case from the Bundibugyo strain in the current outbreak, with Nigeria having one case and Uganda recently declared Ebola-fr...

Scientists Advance Phage-Based Treatments to Combat Antibiotic Resistance

Scientists Advance Phage-Based Treatments to Combat Antibiotic Resistance

Researchers have developed a new method to investigate bacteriophages, or phages, which are viruses that infect and kill bacteria. This innovation aims to enhance understanding of how phages function and to engineer them more effectively against harmful bacteria, particularly in the face of rising antibiotic resistance. The method, called Phage Tn-seq (transposon sequencing), allows scientists to pinpoint essential phage genes and insert new genetic material into their genomes rapidly. This approach leverages the 'molecular arms race' between bacteria and phages, utilizing anti-CRISPR proteins carried on transposons to select for phages with specific mutations. The goal is to overcome limitations of current phage study methods, which are often time-consuming or require extensive prior knowledge of the phage's genome. This development is crucial as antibiotic resistance is projected to contribute to over eight million deaths annually by 2050, renewing interest in phage therapies as an alternative to convent...

Aedes aegypti Mosquito Poses Significant Daytime Disease Threat in U.S.

Aedes aegypti Mosquito Poses Significant Daytime Disease Threat in U.S.

The Aedes aegypti mosquito, also known as the yellow fever mosquito, is a significant daytime feeder and a highly effective vector for diseases such as dengue fever, Zika, chikungunya, and yellow fever. Unlike many other mosquito species that are active at night, Aedes aegypti is most active during the early morning and late afternoon. This species has adapted to human environments, often living indoors or near homes, and preferentially targets human ankles and feet. Female Aedes aegypti can lay eggs in minimal amounts of standing water, even as little as a bottle cap full, making their eradication challenging. While native to Africa, these mosquitoes have spread globally and are now a concern in U.S. states like Texas, Florida, and California, which have temperate climates and large human populations.

Researchers Utilize AI to Predict Cavity Risk Based on Social Determinants of Health

Researchers Utilize AI to Predict Cavity Risk Based on Social Determinants of Health

An international team of researchers is employing artificial intelligence (AI) to identify individuals at high risk for cavities, shifting the focus from individual clinical diagnostics to broader social determinants of health. The findings, published in the journal Caries Research, indicate that AI models can accurately predict cavity risk and severity by analyzing factors such as wealth score, household density, access to fluoridated water, and private dental insurance status. Dr. Fernando Neves Hugo, chair of the Department of Epidemiology and Health Promotion at NYU College of Dentistry and the study's senior author, emphasized that AI offers a transformative opportunity for public health surveillance and risk stratification. The study utilized data from the Brazilian Oral Health Survey, analyzing information from 23,726 participants, including demographic details, socioeconomic factors, and behavioral patterns linked to oral health.

NIST and Department of Energy Collaborate to Repurpose Radioactive Waste for Cancer Treatment

NIST and Department of Energy Collaborate to Repurpose Radioactive Waste for Cancer Treatment

The National Institute of Standards and Technology (NIST) and the Department of Energy (DOE) are collaborating on an initiative to repurpose outdated radioactive materials, previously considered waste, into feedstock for cutting-edge cancer therapies. Manny Mejias, NIST's radiation safety officer, highlighted that research facilities often accumulate outdated radioactive materials, such as radium-226, which were once used in cancer treatment but are no longer medically relevant. Disposing of these materials is costly and poses safety hazards. Through this new program, NIST is providing its legacy radium-226 to the DOE, which will process it into isotopes essential for targeted cancer treatments. This process involves creating custom-made lead cases for safe storage and transport, and rigorous safety protocols are being developed and standardized to allow other institutions to safely transfer their leftover radioactive materials for similar reuse. The goal is to establish a robust domestic supply of these c...